Bolt Biotherapeutics Inc expected to post a loss of 68  cents a share - Earnings Preview

Bolt Biotherapeutics

08/08/2022 12:07

* Bolt Biotherapeutics Inc  BOLT.OQ   BOLT.O  is expected
to show
a rise in quarterly revenue when it reports  results on August
10 (estimated). 
    * The Redwood City California-based  company is expected to
report
revenue of $375 thousand, according to the mean estimate from 4
analysts, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for Bolt
Biotherapeutics Inc
is for a loss of 68 cents per share. For the same quarter last
year, the company reported a loss of 64 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Bolt
Biotherapeutics Inc is $8​, above​ its last closing price
of $2.49. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2022  -0.72       -0.72      -0.64     Beat    10.8
 Dec. 31 2022  -1.43       -0.82      -0.73     Beat    10.8
 Sep. 30 2021  -0.66       -0.65      -0.63     Beat    3.4​
 Jun. 30 2021  -0.43       -0.43      -0.64     Missed  -48.8
 ​​Mar.        -0.60       -0.60      -1.14     Missed  -90
 31 2021                                                
 Dec. 31 2020  -1.80       -1.80      -14.58    Missed  -708.9
                                                        ​
 This summary was machine generated August 8 at 11:07 GMT.  All
figures in US dollars  unless otherwise stated